Helping Life Science Companies With Big Data Challenges

Chief Product Officer (former)

Aigenpulse

Jul 28, 2021PTV-07-21-CL-001-835

Aigenpulse CCO Steven Yemm and CPO Satnam Surae, Ph.D., discuss big data challenges and how their unique data intelligence platform helps companies in the life sciences.

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-14Jul 13, 2026

Preclinical R&D

How Much of Your Last Year’s Research Budget Felt Wasted? The Hidden Cost of Experimental Inconsistencies

Sophie Lutter, Ph.D.; Andrew Chalmers, Ph.D.

Lab Thread

PAO-06-26-CL-05Jun 29, 2026

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-16Jun 29, 2026

Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

PAO-05-26-PA-14May 13, 2026

Lab Software

Lab Thread Introduces Unified Lab Software Platform to Streamline Biological Research

Lab Thread

PR-05-26-01May 8, 2026

Proteomics

RareCyte Expands Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Leadership Appointment

RareCyte

PR-04-26-09Apr 20, 2026

Intercellular

Transferring Cytoplasmic Contents and Organelles Between Living Cells

Waseda University

PR-04-26-06Apr 3, 2026

Laboratory Data

Can Lab Management Software Help Solve the Reproducibility Crisis?

Sophie Lutter, Ph.D.

Lab Thread

PAO-034-26-CL-01Apr 1, 2026

Drug Delivery

Duration Is the New Potency: Why Exposure Control Is Replacing Peak Concentration

David Alvaro, Ph.D.

Pharma's Almanac

PAO-01-26-NI-16Jan 16, 2026

R&D Funding

When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

PAO-01-26-NI-07Jan 9, 2026

EU Overhaul

Europe’s Pharma Overhaul: How the New Incentive Model Will Reshape Global Innovation Strategy

David Alvaro, Ph.D.

Pharma's Almanac

PAO-11-25-NI-06Nov 18, 2025

Organoids

How Organoids Are Continuing to Transform the Path from Bench to Bedside

David Alvaro, Ph.D.

Pharma's Almanac

PAO-10-25-NI-05Oct 16, 2025

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us Nice Insight That's Nice

Reach Our Team

My Account

Subscribe for the newsletter

Subscribe for the Newsletter

Mobile Navigation

Helping Life Science Companies With Big Data Challenges

Related Content

In Vivo Selection

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Preclinical R&D

How Much of Your Last Year’s Research Budget Felt Wasted? The Hidden Cost of Experimental Inconsistencies

Sophie Lutter, Ph.D.; Andrew Chalmers, Ph.D.

Lab Thread

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

Lab Software

Lab Thread Introduces Unified Lab Software Platform to Streamline Biological Research

Lab Thread

Proteomics

RareCyte Expands Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Leadership Appointment

RareCyte

Intercellular

Transferring Cytoplasmic Contents and Organelles Between Living Cells

Waseda University

Laboratory Data

Can Lab Management Software Help Solve the Reproducibility Crisis?

Sophie Lutter, Ph.D.

Lab Thread

Drug Delivery

Duration Is the New Potency: Why Exposure Control Is Replacing Peak Concentration

David Alvaro, Ph.D.

Pharma's Almanac

R&D Funding

When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

EU Overhaul

Europe’s Pharma Overhaul: How the New Incentive Model Will Reshape Global Innovation Strategy

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

How Organoids Are Continuing to Transform the Path from Bench to Bedside

David Alvaro, Ph.D.

Pharma's Almanac

Related Content

In Vivo Selection

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Preclinical R&D

How Much of Your Last Year’s Research Budget Felt Wasted? The Hidden Cost of Experimental Inconsistencies

Sophie Lutter, Ph.D.; Andrew Chalmers, Ph.D.

Lab Thread

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

Lab Software

Lab Thread Introduces Unified Lab Software Platform to Streamline Biological Research

Lab Thread

Proteomics

RareCyte Expands Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Leadership Appointment

RareCyte

Intercellular

Transferring Cytoplasmic Contents and Organelles Between Living Cells

Waseda University

Laboratory Data

Can Lab Management Software Help Solve the Reproducibility Crisis?

Sophie Lutter, Ph.D.

Lab Thread

Drug Delivery